Association between polymorphism of tumor necrosis factor-α promoter and response to lamivudine treatment in patients with chronic hepatitis B

Yong Kwang Park, Jung Min Lee, Do Young Kim, Hye Young Chang, Ja Kyung Kim, Chun Kyon Lee, Jun Yong Park, Sang Hoon Ahn, Kwan Sik Lee, Kwang Hyub Han

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: TNF-α promoter polymorphism is known to play an important role in the immunopathogenesis of infection of hepatitis B virus. Aims: We investigated whether polymorphisms of TNF-α promoter at position -308 or -238 had associations with the response to lamivudine treatment. Methods: A total of 89 healthy subjects (control group) and 225 patients with chronic hepatitis B treated with lamivudine were included in this study. Polymorphisms of TNF-α promoter at position -308 and -238 were analyzed by polymerase chain reaction. Recruited patients were classified according to the outcome of lamivudine treatment into the responder (103 patients) or non-responder (122 patients) group. Results: The numbers of A allelic polymorphism of TNF-α promoter at position -238 were four (2.2%) in the control, five (2.4%) in the responder and 19 (7.8%) in the non-responder group. The A allele was noted significantly more frequently in the responder than non-responder group (P = 0.012). At position -308, a significant difference was observed between the control group (14; 7.9%) and total chronic hepatitis B patients (15; 3.3%) (P = 0.015). Conclusions: Our study demonstrated that the non-response to lamivudine treatment in patients with chronic hepatitis B might be related to the A allelic polymorphism of TNF-α promoter at position -238.

Original languageEnglish
Pages (from-to)2043-2048
Number of pages6
JournalDigestive diseases and sciences
Volume55
Issue number7
DOIs
Publication statusPublished - 2010 Jul 1

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this